Temporal trends in diagnostic work-up, treatment, and mortality in locally advanced prostate cancer in 2016–2024: nationwide, population-based study in Sweden
Acta Oncologica · 15.04.2026 · 65 · 282-288
DOI: 10.2340/ao.v65.45593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Oncologica, online erschienen am 15.04.2026. Verfasst von Armando Galdieri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, I…. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and purpose: We aimed to describe temporal changes in diagnostic work-up, treatment, and prostate cancer (PCa) mortality in locally advanced PCa in 2016–2024 in Sweden. Patient/material and methods: Men registered in the National Prostate Cancer Register of Sweden in 2016–2024 with locally advanced PCa; clinical T stage 3–4, no distant metastases, and prostate-specific antigen < 100 ng/ml were included. We computed the proportion of use of prostate magnetic resonance imaging (MRI) before biopsy, radical prostatectomy, radical radiotherapy, androgen deprivation therapy, and abiraterone, and described the trend in PCa mortality across three calendar periods.
Results
During the 9-year study period 7,484 men with locally advanced PCa were identified. Use of MRI before biopsy increased from 3% in 2016 to 73% in 2024. Concomitantly, radical treatment increased from 35% to 48%, entirely due to increased use of radiotherapy. Abiraterone was not used before 2022 but 31% received this treatment in 2024. The 3-year PCa mortality decreased from 8% (95% confidence interval [CI]: 7–9) in 2016–2018 to 6% (95% CI: 4–8) in 2022–2024.
Interpretation
In this nationwide, population-based study of men with locally advanced PCa, the use of MRI before biopsy, radical radiotherapy, and treatment with abiraterone increased over time. These changes coincided with a modest decrease in 3-year PCa mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San…
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. marcus.westerberg@uu.se.
ORCID-Profile: Armando Galdieri, Hans Garmo, Rolf Gedeborg, Mats Ahlberg, Andri Wilberg Orrason, Eugenio Ventimiglia, Pär Stattin, Marcus Westerberg
Zitieren
APA
Galdieri, A., Garmo, H., Gedeborg, R., Ahlberg, M., Orrason, A. W., Ventimiglia, E., Stattin, P., & Westerberg, M. (2026). Temporal trends in diagnostic work-up, treatment, and mortality in locally advanced prostate cancer in 2016–2024: nationwide, population-based study in Sweden. Acta Oncologica, 65, 282-288. https://doi.org/10.2340/ao.v65.45593
Vancouver
Galdieri A, Garmo H, Gedeborg R, Ahlberg M, Orrason AW, Ventimiglia E, et al. Temporal trends in diagnostic work-up, treatment, and mortality in locally advanced prostate cancer in 2016–2024: nationwide, population-based study in Sweden. Acta Oncologica. 2026;65:282-288. doi:10.2340/ao.v65.45593
BibTeX
@article{Galdieri2026,
author = {Galdieri, Armando and Garmo, Hans and Gedeborg, Rolf and Ahlberg, Mats and Orrason, Andri Wilberg and Ventimiglia, Eugenio and Stattin, Pär and Westerberg, Marcus},
title = {Temporal trends in diagnostic work-up, treatment, and mortality in locally advanced prostate cancer in 2016–2024: nationwide, population-based study in Sweden},
journal = {Acta Oncologica},
year = {2026},
volume = {65},
pages = {282--288},
doi = {10.2340/ao.v65.45593}
}
EUVIMED